Drug
Z 338 clinical trials
Also written Z-338, Acotiamide and YM443.
- studies test it
- 14
- open now
- 2
- in phase 3
- 5
- first study started
- 2004
Keep track of what changes. Save the Z 338 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2014 | 1 |
| 2017 | 1 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 5
- Phase 3
- 5
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 2
Zeria Pharmaceutical (7) · Astellas Pharma Inc (4) · Universitaire Ziekenhuizen KU Leuven (1) · Aga Khan University (1) · Getz Pharma (1)
Studies
Open first, then newest update. How each study uses Z 338 is read from its arms, and is right about nine times in ten.
Testing it · 14
- Comparing Acotiamide and Itopride for the Management of IndigestionNot yet recruitingPhase 4Aga Khan UniversityNCT07449689Written as Acotiamide
- Acotiamide vs Itopride in Postprandial Distress SyndromeNot yet recruitingPhase 3Getz PharmaNCT07174297Written as Acotiamide
- A Phase III Trial of Z-338 in Paediatric Patients With Functional DyspepsiaCompletedPhase 3Zeria PharmaceuticalNCT04526119Written as Acotiamide hydrochloride hydrate
- Effect of Acotiamide on Gastric Motility and Satiation in Healthy VolunteersCompletedNot applicableUniversitaire Ziekenhuizen KU LeuvenNCT03402984Written as Acotiamide
- YM443 in Subjects With Functional DyspepsiaCompletedPhase 2Astellas Pharma IncNCT00102310Written as YM443
- Phase III, Long-term, Open-label Safety Study of Z-338CompletedPhase 3Zeria PharmaceuticalNCT01973790Written as Z-338
- To Evaluate the Efficacy and Safety in Subjects With Functional DyspepsiaCompletedPhase 2Zeria PharmaceuticalNCT00323817Written as Z-338
- A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional DyspepsiaCompletedPhase 3Astellas Pharma IncNCT00764374Written as YM443
- A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy AdultsCompletedPhase 1Astellas Pharma IncNCT00850746Written as YM443
- To Verify the Efficacy of Z-338 in Subjects With Functional DyspepsiaCompletedPhase 3Zeria PharmaceuticalNCT00761358Written as Z-338
- The Effect of Z-338 in Subjects With Functional DyspepsiaCompletedPhase 2Zeria PharmaceuticalNCT00458328Written as Z-338
- Effect of Food Intake on Pharmacokinetic Profiles of Z-338CompletedPhase 1Astellas Pharma IncNCT00920998Written as Z-338
- The Effects of Z-338 in Subjects With and Without Functional DyspepsiaCompletedPhase 2Zeria PharmaceuticalNCT00298194Written as Z-338
- To Evaluate the Efficacy of Z-338 in Subjects With Functional DyspepsiaCompletedPhase 2Zeria PharmaceuticalNCT00333372Written as Z-338
As the comparator · 1 — what is tested is compared with Z 338
Codes
What other systems call Z 338 · ClinicalTrials.gg INT004252
- MeSH (NLM) C410959Z 338Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) D42OWK5383ACOTIAMIDEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C410959 | Z 338 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | D42OWK5383 | ACOTIAMIDE | Confirmed FDA, NLM |
Also registered as acotiamide hydrochloride (UNII NMW7447A9A).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.